Clinical Trials · NCT00701935
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- AstraZeneca
- Enrollment
- 80
- Start date
- Aug 2008
- Locations
- 17 sites, United States, Canada
- Primary endpoint
- Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months